Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Belumosudil mesylate

Given by PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Sanofi US Services, Inc

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER